Can we interpret serum thyroglobulin results?

Annals of Clinical Biochemistry

Volumn 49, Issue 4, 2012, Pages 313-322

  Clark, Penny ^a   Franklyn, Jayne ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROPHILE ANTIBODY; IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROXINE;

ABLATION THERAPY; ASPIRATION CYTOLOGY; CANCER OF UNKNOWN PRIMARY SITE; CERVICAL LYMPHADENOPATHY; CLINICAL DECISION MAKING; COLOR ULTRASOUND FLOWMETRY; CONGENITAL HYPOTHYROIDISM; DIFFERENTIATED THYROID CANCER; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GROUPS BY AGE; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; IMMUNOASSAY; IMMUNOCHEMILUMINESCENT ASSAY; IMMUNOMETRIC ASSAY; INTERMETHOD COMPARISON; LABORATORY DEVICE; LABORATORY DIAGNOSIS; LABORATORY TEST; LYMPH NODE METASTASIS; NEEDLE BIOPSY; NODULAR GOITER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENT CANCER; REVIEW; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; THYROGLOBULIN BLOOD LEVEL; THYROID ADENOMA; THYROID DISEASE; THYROID DYSGENESIS; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

CHILD; FEMALE; HUMANS; NEOPLASM METASTASIS; PREGNANCY; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867124412     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011248     Document Type: Review

References (87)

1. Cancer Research UK. Cancer Statistics 2007. See http://infocancerresearchuk.org/cancerstats/types/thyroid/incidence/(last checked 27 July 2010)
2. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in the community: the Whickham survey. Clin Endocrinol 1977;7:481-93.
3. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus to evidence-based practice. Thyroid 2009;19:1167-214.
5. Perros P, Clarke SEM, Franklyn J, et al. In: Perros P, ed. British Thyroid Association and Royal College of Physicians Guidelines for the Management of Thyroid Cancer. 2nd edn. 2007. See http://www.british-thyroidassociation. org/Guidelines/ (last checked 7 February 2012)
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
7. Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1987;27:115-20.
8. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid cancer. J Clin Endocrinol Metab 1998;83:1121-7.
9. Clark PM. Laboratory services for thyroglobulin and implications for monitoring of differentiated thyroid cancer. J Clin Pathol 2009;62:402-6.
10. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223-33.
11. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001;25:632-7.
12. Gerenova J, Buysschaert M, de Burbure CY, Daumerie C. Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med 2003;14:321-5.
13. Pacini F, Pinchera A, Giani C, Grasso L, Doveri F, Baschieri L. Serum thyroglobulin in thyroid carcinoma and other thyroid disorders. J Endocrinol Invest 1980;3:283-92.
14. Snozek CLH, Chambers EP, Reading CC, et al. Serum thyroglobulin, high-resolution ultrasound and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007;92:4278-81.
15. Boi F, Baghino G, Alzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006;91:1364-9.
16. Frasoldati A, Toschi E, Zini M, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid 1999;9:105-11.
17. Borel A-L, Boizel R, Faure P, et al. Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer. Eur J Endocrinol 2008;158:691-8.
18. Edmonds CJ, Willis CL. Serum thyroglobulin in the investigation of patients presenting with metastases. Br J Radiol 1988;61:317-9.
19. Torrigiani G, Doniach D, Roitt IM. Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease. J Clin Endocrinol 1968;29:305-14.
20. BNF 61 Thyrotropin Alfa. See www.bnf.org (last checked 18 July 2011)
21. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001;86:1660-4.
22. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
23. Spencer CA, Wang CC. Thyroglobulin measurements: techniques, clinical benefits and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-63.
24. Robbins RJ, Robbins AK. Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8.
25. Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008;22:1009-21.
26. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7
27. Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharmaceut 2000;15:211-7.
28. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-25.
29. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90.
30. Mazzaferri EL, Kloos RT. Is diagnostic Iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroids ablation. J Clin Endocrinol Metab 2002;87:1490-8.
31. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-57.
32. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.
33. Malandrino P, Latina A, Marescalco S, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011;96:1703-9.
34. Brassard N, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352-9.
35. Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007;67:434-41.
36. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-95.
37. Feldt-Rasmussen U, Profilis C, Colinet R, et al. Human thyroglobulin reference material (CRM 457). 1st Part: assessment of homogeneity, stability and immunoreactivity. Ann Biol Clin (Paris) 1996;54:337-42.
38. Feldt-Rasmussen U, Profilis C, Colinet R, et al. Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification. Ann Biol Clin (Paris) 1996;54:343-8.
39. Powell R, Hudson LC, Lambirth KC, et al. Recombinant expression of homodimeric 660 kDa human thyroglobulin in soybean seeds: an alternative source of human thyroglobulin. Plant Cell Rep 2011;30:1327-38.
40. MacKenzie F. UKNEQAS Thyroglobulin Surveys. March 2011
41. Mazzaferri EL. Will highly sensitive thyroglobulin assays change the management of thyroid cancer? Clin Endocrinol (Oxf) 2007;67:321-3
42. Dittadi R, Peloso L, Gion M. Within-subject biological variation in disease: the case of tumour markers. Ann Clin Biochem 2008;45:226-8.
43. Jensen E, Petersen JH, Blaabjerg O, et al. Biological variation of thyroid autoantibodies and thyroglobulin. Clin Chem Lab Med 2007;45:1058-64.
44. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011;21:707-16.
45. Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997;23:208-10.
46. Oduncu FS, Kimmig R, Hepp H, Emmerich B. Cancer in pregnancy: maternal-fetal conflict. J Cancer Res Clin Oncol 2003;129:133-46.
47. Holt EH. Care of the pregnant thyroid cancer patient. Curr Opin Oncol 2010;22:1-5.
48. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92(Suppl.):S1-47
49. Mazzaferri EL. Approach to the pregnant patient with thyroid cancer. J Clin Endocrinol Metab 2011;96:265-72.
50. Mandel SJ, Spencer CA, Hollowell JG. Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid 2005;15:44-53
51. Nakamura S, Sakata S, Komaki T, et al. Serum thyroglobulin concentrations in normal pregnancy. Endocrinol Jpn 1984;31:675-9.
52. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. Trimester-specific changes in maternal thyroid hormone, thyrotropin and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid 2004;14:1084-90.
53. Eltom A, Elnagar B, Elbagir M, Gebre-Medhin M. Thyroglobulin in serum as an indicator of iodine status during pregnancy. Scand J Clin Lab Invest 2000;60:1-7.
54. Rosen IB, Korman M, Walfish PG. Thyroid nodular disease in pregnancy: current diagnosis and management. Clin Obstet Gynaecol 1997;40:81-9.
55. Josefson J, Zimmerman D. Thyroid nodules and cancers in children. Pediatr Endocrinol Res 2008;6:14-23.
56. Penny R, Spencer CA, Frasier SD, Nicoloff JT. Thyroid-stimulating hormone and thyroglobulin levels decrease with chronological age in children and adolescents. J Clin Endocrinol Metab 1983;56:177-9.
57. Pezzino V, Filetti S, Belfiore A, Proto S, Donzelli G, Vigneri R. Serum thyroglobulin levels in the newborn. J Clin Endocrinol Metab 1981;52:364-6.
58. Eltom A, Eltom M, Idris I, Gebre-Medhin M. Thyroid function in the newborn in relation to maternal thyroid status during labour in a mild iodine deficiency endemic area in Sudan. Clinical Endocrinol 2001;55:485-90.
59. Ares S, Escobar-Morreale HF, Queri J, et al. Neonatal hypothyroxinemia: effects of iodine intake and premature birth. J Clin Endocrinol Metab 1997;82:1704-12.
60. Kok JH, Tegelaers WHH, Vijlder JJM. Serum thyroglobulin in preterm infants with and without respiratory distress syndrome. II A longitudinal study during the first three weeks of life. Pediatr Res 1986;20:1001-3.
61. UK National Newborn Screening Programme Centre. Newborn Blood Spot Screening in the UK. Policies and Standards. London: Department of Health; 2005
62. Grúters A, Krude H, Biebermann H. Molecular genetic defects in congenital hypothyroidism. Eur J Endocrinol 2004;151:U39-U44
63. Ilicki A, Ericsson U-B, Larsson A, et al. The value of neonatal serum thyroglobulin determinations in the follow-up of patients with congenital hypothyroidism. Acta Paediatr Scand 1990;79:769-75.
64. Beltraõ CB, Juliano AG, Chammas MC, et al. Etiology of congenital hypothyroidism using thyroglobulin and ultrasound combination. Endocrine J 2010;57:587-93.
65. Clerc J, Monpeyssen H, Chevalier A, et al. Scintigraphic imaging of paediatric thyroid dysfunction. Hormone Res 2008;70:1-13.
66. Mariotti S, Martino E, Cupini C, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med 1982;307:410-2.
67. Schneider AB, Pervos R. Radioimmunoassay of human thyroglobulin:effect of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978;47:126-37.
68. Tozzoli R, Bizzaro N, Tonutti E, et al. Immunoassay of anti-thyroid autoantibodies: high analytical variability in second generation methods. Clin Chem Lab Med 2002;40:568-73.
69. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75.
70. Okosieme OE, Evans C, Moss L, et al. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin Chem 2005;51:729-34.
71. Gao Y, Yuan Z, Yu Y, Lu H. Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay. Clin Biochem 2007;40:735-8.
72. Aras G, Gültekin SS, Kü çük NO. The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid carcinoma. Nucl Med Commun 2008;29:880-4.
73. Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72:558-63.
74. Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol 2002;57:215-21.
75. Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:4683-9.
76. Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: A prospective study. J Nucl Med 1992;33:1478-80.
77. Algeciras-Schimnich A, Lasho MA, Ness KM, et al. The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter Access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 2011;21:813-4.
78. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:1283-91.
79. Taylor KP, Parkington D, Bradbury S, Simpson HL, Jefferies SJ, Halsall DJ. Concordance between serum thyroglobulin antibody assays. Ann Clin Biochem 2011;48:367-9.
80. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153:49-55.
81. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51.
82. Giovanella L, Suriano S, Ceriani L, et al. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med 2011;36:109-12.
83. Ross HA, Netea-Maier RT, Schakenraad E, Bravenboer B, Hermus ARMM, Sweep FCGJ. Assay bias may invalidate decision limits and affect comparability of serum thyroglobulin assay methods: an approach to reduce interpretation differences. Clin Chim Acta 2008;394:104-9.
84. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SKG. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-74.
85. Verburg FA, Wäschle K, Reiners C, Giovanella L, Lentjes EGWM. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer. Hormone Metab Res 2010;42:736-9.
86. Giovanella L, Ghelfo A. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. Clin Chem 2007;53:1871-2.
87. Massart C, Corcuff J-B, Bordenave L. False-positive results corrected by the use of heterophilic antibody-blocking reagent in thyroglobulin immunoassays. Clin Chim Acta 2008;388:211-3.